Recently, antagonistic humanized anti-BCMA antibody-drug conjugates via a noncleavable linker with auristatins (monomethyl auristatin E, MMAE or monomethyl auristatin F, MMAF) in preclinical studies demonstrated impressive in vitro and in vivo anti-multiple myeloma activity [105,111]. Here, TNFRSF17 is linked to AL amyloidosis.